THE WIRE · № 80758
Trial Demonstrates Feasibility of At-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema
01 THE MACHINE READ
WHY IT MATTERS.
At-home subcutaneous diuretics cutting inpatient days could shift heart-failure care away from hospitals, pressuring inpatient revenue while aiding payers.
Care-shift trial could cut heart-failure admissions
Phase 3 data and payer coverage decisions
Small trial, adoption and reimbursement uncertain
FULL DISPATCH
Patients self-administered a hospital-equivalent diuretic treatment resulting in a reduction of approximately 4 inpatient days per episode, according to study published in the Journal of the American College of Cardiology. BURLINGTON, Mass., Oct. 14, 2026 /PRNewswire/ -- SQ Innovation...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
The Rundown: A proposed Chicago-area healthcare merger2026-10-14 20:45 UTC
Aurora Cannabis Reiterates Opposition to Curaleaf's Takeover Offer2026-10-14 20:25 UTC
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program2026-10-14 21:00 UTC
Big-ticket hospital deals are becoming the M&A story of 20262026-10-14 21:00 UTC
Calls mount for NC attorney general to review ‘rushed’ WakeMed-Atrium merger2026-10-14 21:36 UTC
FLSC IPO News - Biotech-focused SPAC Frazier Life Sciences Acquisition II prices $75 million IPO2026-10-14 12:32 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.